Patent on Technology for the Delivery of Stem Cells to the Human Heart Issued to CellCyte Genetics Corp. of Washington
KIRKLAND, Wash., Nov. 9 /PRNewswire-FirstCall/ -- CellCyte Genetics
Corporation (OTC Bulletin Board: CCYG) announced today that is has received
notice of the issuance of a U.S. patent (U.S. Patent No. 7,282,222) for its
unique methods and compositions approach to deliver and direct stem cells
to target organs in the body.
Using this now-patented technology, exclusively licensed to CellCyte
from the US Department of Veterans Affairs, the company is developing stem
cell enabling therapeutic products designed to allow more efficient
delivery and significantly increased retention of adult stem cells to
diseased and other target organs, such as the heart.
Dr. Ronald Berninger, Chief Scientific Officer of CellCyte Genetics
explains, "The goal of CellCyte's stem cell targeting/retention therapies
is to enhance the number of cells available for regeneration of damaged
tissue, and thereby markedly increase opportunities for healing and
restoring organ function. The company's first product in development,
CCG-TH30, is designed to target autologous bone-marrow-derived (adult) stem
cells to the heart of patients after a heart attack."
"In preclinical models, CCG-TH30 has been shown to increase the
retention of stem cells up to as much as 77% in pre-clinical models as
compared to conventional methods, which achieve only up to about 6%,"
Berninger states. "Importantly, CellCyte's product candidate, along with
stem cells, can both be delivered intravenously through a patient's
circulatory system without an invasive procedure."
Company CEO, President and Chairman, Gary A. Reys emphasizes the
importance of the patent's issuance to the company's position. Reys states,
"This patented technology is significant, as it has the potential to fill
an important missing piece in the field of regenerative medicine, namely,
the ability to target and then keep cells in an organ of interest, in this
case, the heart. The issuance of a patent for this platform assures
CellCyte Genetics that it will remain a leader in this field as it
continues to pursue development of the technology to deliver stem cells to
other areas throughout the body."
CellCyte Genetics Corp. is completing preclinical studies and in 2008
will then move to a Phase I human clinical trial using the compound for the
heart.
In addition to this indication, the patenting of the technology opens
up the possibility for gene therapy and the delivery of a variety of other
payloads to the heart via the stem cell vehicle.
About CellCyte Genetics
CellCyte Genetics, a Washington State company, is an emerging
biotechnology company engaged in the principle business of the discovery,
development and commercialization of breakthrough stem cell enabling
therapeutic products.
For further information see: www.cellcyte.com.
Symbol: OTCBB - CCYG; Frankfurt/Berlin Symbol - LK6 WKN. No.: A0MLCV.
Safe Harbor Statement
THIS NEWS RELEASE CONTAINS "FORWARD-LOOKING STATEMENTS", AS THAT TERM
IS DEFINED IN SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS
AMENDED, AND SECTION 21E OF THE UNITED STATES SECURITIES EXCHANGE ACT OF
1934, AS AMENDED. STATEMENTS IN THIS NEWS RELEASE, WHICH ARE NOT PURELY
HISTORICAL, ARE FORWARD-LOOKING STATEMENTS AND INCLUDE ANY STATEMENTS
REGARDING BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS REGARDING THE FUTURE.
EXCEPT FOR THE HISTORICAL INFORMATION PRESENTED HEREIN, MATTERS DISCUSSED
IN THIS NEWS RELEASE CONTAIN FORWARD-LOOKING STATEMENTS THAT ARE SUBJECT TO
CERTAIN RISKS AND UNCERTAINTIES THAT COULD CAUSE ACTUAL RESULTS TO DIFFER
MATERIALLY FROM ANY FUTURE RESULTS, PERFORMANCE OR ACHIEVEMENTS EXPRESSED
OR IMPLIED BY SUCH STATEMENTS. STATEMENTS THAT ARE NOT HISTORICAL FACTS,
INCLUDING STATEMENTS THAT ARE PRECEDED BY, FOLLOWED BY, OR THAT INCLUDE
SUCH WORDS AS "ESTIMATE," "ANTICIPATE," "BELIEVE," "PLAN" OR "EXPECT" OR
SIMILAR STATEMENTS ARE FORWARD- LOOKING STATEMENTS. RISKS AND UNCERTAINTIES
FOR THE COMPANY INCLUDE, BUT ARE NOT LIMITED TO, THE RISKS ASSOCIATED WITH
THE CLOSING OF THE CLOSING OF THE SHARE EXCHANGE AGREEMENT AND THE
DEVELOPMENT AND FUNDING OF THE COMPANY CONSEQUENT THEREON, AS WELL AS THE
RISKS SHOWN IN THE COMPANY'S MOST RECENT ANNUAL REPORT ON FORM 10-KSB AND
ON FORM 10-QSB AND FROM TIME-TO-TIME IN OTHER PUBLICLY AVAILABLE
INFORMATION REGARDING THE COMPANY. OTHER RISKS INCLUDE RISKS ASSOCIATED
WITH THE REGULATORY APPROVAL PROCESS, COMPETITIVE COMPANIES, FUTURE CAPITAL
REQUIREMENTS AND THE COMPANY'S ABILITY AND LEVEL OF SUPPORT FOR ITS
RESEARCH AND DEVELOPMENT ACTIVITIES. THERE CAN BE NO ASSURANCE THAT THE
COMPANY'S DEVELOPMENT EFFORTS WILL SUCCEED AND THE COMPANY WILL ULTIMATELY
ACHIEVE COMMERCIAL SUCCESS.
THESE FORWARD-LOOKING STATEMENTS ARE MADE AS OF THE DATE OF THIS NEWS
RELEASE, AND THE COMPANY ASSUMES NO OBLIGATION TO UPDATE THE
FORWARD-LOOKING STATEMENTS, OR TO UPDATE THE REASONS WHY ACTUAL RESULTS
COULD DIFFER FROM THOSE PROJECTED IN THE FORWARD-LOOKING STATEMENTS.
ALTHOUGH THE COMPANY BELIEVES THAT THE BELIEFS, PLANS, EXPECTATIONS AND
INTENTIONS CONTAINED IN THIS NEWS RELEASE ARE REASONABLE, THERE CAN BE NO
ASSURANCE THOSE BELIEFS, PLANS, EXPECTATIONS OR INTENTIONS WILL PROVE TO BE
ACCURATE. INVESTORS SHOULD CONSIDER ALL OF THE INFORMATION SET FORTH HEREIN
AND SHOULD ALSO REFER TO THE RISK FACTORS DISCLOSED IN THE COMPANY'S
PERIODIC REPORTS FILED FROM TIME-TO- TIME WITH THE UNITED STATES SECURITIES
AND EXCHANGE COMMISSION. THIS NEWS RELEASE HAS BEEN PREPARED BY MANAGEMENT
OF THE COMPANY WHO TAKE FULL RESPONSIBILITY FOR ITS CONTENTS. EACH OF THE
NASD, THE SEC AND THE OTCBB NEITHER APPROVES NOR DISAPPROVES OF THE
CONTENTS OF THIS NEWS RELEASE. THIS NEWS RELEASE SHALL NOT CONSTITUTE AN
OFFER TO SELL OR THE SOLICITATION OF AN OFFER TO BUY NOR SHALL THERE BE ANY
SALE OF THESE SECURITIES IN ANY JURISDICTION IN WHICH SUCH OFFER,
SOLICITATION OR SALE WOULD BE UNLAWFUL PRIOR TO REGISTRATION OR
QUALIFICATION UNDER THE SECURITIES LAWS OF ANY SUCH JURISDICTION.
SOURCE CellCyte Genetics Corporation
